fda glp-1 enforcement news Beyond the Headlines: Warning Letters to Compounders FDA cracks down on 'misleading'

Results showed a steady increase in glutathione levels when compared to the baseline

Cherney DZ, Dekkers CC, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, et al

Acknowledgements This work is supported by the Junior Group Leader program of the Rudolf Virchow Center, University of Wrzburg and Deutsche Forschungsgemeinschaft (DFG) FR 3746/3-1 to J.P.F.A., the DFG CO 291/5-2 and CO 291/7-1, the German Federal Ministry of Education and Research (BMBF) through the Joint Project Modelling ALS Disease In vitro (MAIV, 01EK1611B) and the VIP+ program NEUROPROTEKT (03VP04260), as well as the m 4 Award provided by the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi) to M.C., the Cancer Research UK (CRUK, grants C29637/A20183 and C29637/A21451) to E.W.T., the European Research Council (LipidArrays) to V.O., the Natural Sciences and Engineering Council of Canada and the Canada Foundation for Innovation to D.A.P

The Ozempic ladder reaches 2.0 mg weekly, but doubling from 1.0 to 2.0 mg added only about 0.23 percentage points of HbA1c reduction and 0.9 kg of weight loss. Beyond 1.0 mg, most of the added effect is on weight rather than glucose

In renal cancer cells, increased expression of the E3 ligase UBE3C increased the expression level of Phosphatidylethanolamine Binding Protein 1 (PEBP1)